コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 mum time off between shifts through an ACGME waiver.
2 s performed under institutional review board waiver.
3 income immigrants eligible for a federal fee waiver.
4 migrants about their eligibility for the fee waiver.
5 nternational medical graduates with J-1 visa waivers.
6 likely to enhance state flexibility through waivers.
7 t were covered by insurers with cost-sharing waivers.
12 onal review board approval, informed consent waiver, and HIPAA compliance, a prospective observationa
16 sociated with an increase in the number of X-waivered clinicians but was not consistently associated
18 ntucky showed an increase in the number of X-waivered clinicians prescribing buprenorphine associated
20 1 (48.4%) had received an X-waiver; of these waivered clinicians, 22 (36%) were prescribing buprenorp
23 evel variables showed that, among areas with waivered clinicians, clinicians practicing in more popul
24 New Centers for Medicare & Medicaid Services waivers created a payment mechanism for hospital at home
25 r practice and more expedited care, 2) State waiver did not change practice either because of pre-est
26 their plans did not implement waivers or if waivers did not capture all hospitalization-related care
29 s identified four themes including: 1) State waivers enabled more control over practice and more expe
32 aiver episodes increased from 6% to 32%, and waiver episodes without preceding acute care increased f
33 f difficulty obtaining deidentified data and waivers, experiences with multisite studies, and perceiv
35 is, ID physicians had lower odds of having a waiver for every 10-year increase since graduating medic
37 n institutional review board exemption and a waiver for informed consent were granted to the author w
39 ether removal of the requirement to obtain a waiver for prescribing buprenorphine through the Drug Ad
40 and 2012 and provided informed consent or a waiver for research, in compliance with HIPAA regulation
41 eview board approval and an informed consent waiver for this retrospective HIPAA-compliant study were
45 tric Regulation facilitates paediatric class waivers for drugs developed for diseases only occurring
46 Medicaid home- and community-based services waivers for individuals 65 years or older or those with
47 pharmacologic treatment in office settings, waivers for the use of new medications, and new rules go
48 equired qualified practitioners to receive a waiver from the Drug Enforcement Agency to prescribe bup
49 es in the numbers of ED clinicians with an X-waiver (from 11 to 196 clinicians) and ED visits with pr
50 linicians previously required a practitioner waiver (i.e., "DATA-waiver" or "X-waiver") to offer bupr
53 e introduced a public health emergency (PHE) waiver in March 2020, removing a 3-day hospitalization r
54 2019 (COVID-19) pandemic, federal emergency waivers in the United States enabled kidney care provide
56 rvices, suggesting that insurer cost-sharing waivers may not have covered all hospitalization-related
58 nd data repositories and the standards for a waiver of authorization for disclosure and use of such d
60 n trial, while 33 studies (46.5%) received a waiver of authorization from the respective ethical revi
62 research purposes (ie, with authorization or waiver of authorization, when only a limited data set is
66 ng institutional review board approval, with waiver of consent and with HIPAA compliance, the authors
67 institutional review board concern regarding waiver of consent as a major barrier to approval and wer
69 formed consent from prospective subjects and waiver of consent from retrospective subjects) were stud
73 with approval for consenting processes or a waiver of consent to enroll participants, link data, and
74 passive consenting processes or to obtain a waiver of consent to enroll participants, link data, and
75 r to initial sample collection; otherwise, a waiver of consent was granted, and deferred consent was
79 Institutional review board approval and a waiver of consent were obtained for this retrospective H
80 lity and Accountability Act compliance under waiver of consent, a cohort of women from the American C
91 s HIPAA-compliant study was performed with a waiver of informed consent after institutional review bo
96 This IRB-approved, HIPAA-compliant study had waiver of informed consent and retrospectively reviewed
99 onal review board approval was received with waiver of informed consent for medical record reviews.
100 btained for this HIPAA-compliant study, with waiver of informed consent for retrospective medical rec
101 d approval was obtained for this study, with waiver of informed consent for retrospective review of m
102 oved this HIPAA-compliant study and issued a waiver of informed consent for review of the MR reports
103 AND The institutional review board issued a waiver of informed consent for this HIPAA-compliant stud
104 itutional review board approved and issued a waiver of informed consent for this HIPAA-compliant stud
105 al from the institutional review board, with waiver of informed consent for this retrospective review
106 ity Act-compliant study was performed with a waiver of informed consent from the institutional review
107 s HIPAA-compliant study was performed with a waiver of informed consent from the institutional review
109 eview boards to approve their conduct with a waiver of informed consent if obtaining informed consent
110 PAA-compliant, prospective cohort study with waiver of informed consent in patients with primary brea
111 stitutional review board-approved study with waiver of informed consent included all adults admitted
112 ed, HIPAA-compliant retrospective study with waiver of informed consent included all patients who wer
113 ved HIPAA-compliant retrospective study with waiver of informed consent included patients with asympt
114 institutional review board interpretation of waiver of informed consent regulations was cited as a ma
115 ective study was compliant with HIPAA, and a waiver of informed consent was approved by the instituti
119 al review board approval was obtained, and a waiver of informed consent was granted for this HIPAA-co
120 AND Institutional review board approval with waiver of informed consent was obtained for this Health
121 in compliance with HIPAA regulations, and a waiver of informed consent was obtained from the institu
122 r institutional review board approval with a waiver of informed consent was obtained, a HIPAA-complia
129 d, HIPAA-compliant retrospective review with waiver of informed consent was performed to evaluate all
131 Institutional review board approval and waiver of informed consent were obtained as part of this
132 Institutional review board approval and a waiver of informed consent were obtained for this HIPAA-
133 Institutional review board approval and waiver of informed consent were obtained for this HIPAA-
134 Institutional review board approval and waiver of informed consent were obtained for this HIPAA-
138 Duke University Health System approved (with waiver of informed consent) this retrospective analysis
139 is institutional review board-approved (with waiver of informed consent), HIPAA-compliant study, 38 f
140 view board-approved retrospective study with waiver of informed consent, 247 patients (196 men, 51 wo
142 al review board approval was obtained with a waiver of informed consent, and the study complied with
143 d by the committee on human research, with a waiver of informed consent, and was compliant with HIPAA
144 oved by the institutional review board, with waiver of informed consent, and was compliant with the H
145 oved by the institutional review board, with waiver of informed consent, and was in compliance with H
146 d, HIPAA-compliant retrospective study, with waiver of informed consent, databases were searched for
147 their local institutional review board, with waiver of informed consent, for this HIPAA-compliant stu
148 a waiver of authorization, which included a waiver of informed consent, for this HIPAA-compliant stu
149 Institutional review board approval, with a waiver of informed consent, was obtained for this analys
150 Institutional review board approval, with waiver of informed consent, was obtained for this retros
222 pt status for this retrospective study, with waiver of informed consent; patient data were collected
225 l review board approval was obtained, with a waiver of patient informed consent for this HIPAA-compli
230 institutional review board approval, with a waiver of the HIPAA requirement for informed consent.
231 pproval of the Hospital Ethics Committee and waiver of the informed consent requirement, data in 102
238 Committee on Human Research approval, with waiver of the requirement for informed consent, was obta
241 rbal consent for prospective low-dose CT and waivers of consent for retrospective review of CT scans
243 With institutional review board approval, waivers of informed consent, and in compliance with HIPA
249 approved by institutional review board with waivers of informed written consent and included consecu
250 ent numbers of youth, obtaining approval for waivers of parental consent, and high attrition in longi
251 who responded, 61 (48.4%) had received an X-waiver; of these waivered clinicians, 22 (36%) were pres
252 ic Regulation, which allows product-specific waivers on the grounds that the associated condition doe
253 n the rate of practitioners with a DATA 2000 waiver or buprenorphine prescribing among those waivered
254 l characteristics, impact metrics, APCs, and waiver or discount were extracted from the National Libr
256 rnal websites with information regarding fee waivers or discounts, 7 journals (35%) confirmed fee wai
257 been billed if their plans did not implement waivers or if waivers did not capture all hospitalizatio
259 required a practitioner waiver (i.e., "DATA-waiver" or "X-waiver") to offer buprenorphine, a medicat
261 the impact of the standardization of the fee-waiver process in 2010 by the US Citizenship and Immigra
265 e prescriptions due to factors such as "DATA-waiver" providers underutilizing their buprenorphine pre
267 we find that the positive effect of the fee-waiver reform was concentrated among the subgroups of im
273 program (FSP) under a Medicaid Section 1115 waiver to address food and housing insecurity for accoun
274 harge OR for soldiers who required a medical waiver to enter the army (OR: 1.56; 95% CI: 1.48, 1.64)
275 national registry of clinicians possessing a waiver to legally prescribe buprenorphine (ie, waivered
276 ruitment bias was avoided through an ethical waiver to patient consent; a mixture of rural, urban, di
277 luded the numbers of ED clinicians with an X-waiver to prescribe buprenorphine and ED visits with bup
278 d to increase the workforce of ID physicians waivered to prescribe buprenorphine and a call for incre
279 19) public health emergency, Medicare issued waivers to allow virtual CR; it is unclear whether these
280 at patients may experience if insurers allow waivers to expire, as many chose to do during 2021.
282 practitioners and physician assistants with waivers to prescribe buprenorphine for treating opioid u
283 actitioner waiver (i.e., "DATA-waiver" or "X-waiver") to offer buprenorphine, a medication for opioid
285 ed to understand whether the relaxation of X-waiver training requirements for prescribing buprenorphi
286 erial cross-sectional study, relaxation of X-waiver training requirements was associated with an incr
288 crease substantially; for LTC residents, the waiver was applied primarily for COVID-19 care, suggesti
290 Patient consent was not required; a HIPAA waiver was granted because of the retrospective nature o
298 and in the Army's increased use of accession waivers (which relaxed some qualifications for new soldi
299 llow virtual CR; it is unclear whether these waivers will become permanent policy post-public health
300 e Drug Addiction Treatment Act of 2000 (an X-waiver) will be enough to increase access to buprenorphi